Dabigatran
- Generic Name
- Dabigatran
- Brand Names
- Dabigatran Etexilate Leon Farma, Dabigatran Etexilate Accord, Pradaxa
- Drug Type
- Small Molecule
- Chemical Formula
- C25H25N7O3
- CAS Number
- 211914-51-1
- Unique Ingredient Identifier
- I0VM4M70GC
- Background
Dabigatran is the active form of the orally bioavailable prodrug dabigatran etexilate.
- Associated Conditions
- -
- Associated Therapies
- -
Replication Of An Early Evaluation Of 30-Day Readmissions Among Nonvalvular Atrial Fibrillation Patients Treated With Dabigatran, Rivaroxaban, Apixaban, or Warfarin In The U.S
- Conditions
- Interventions
- First Posted Date
- 2016-05-11
- Last Posted Date
- 2016-05-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 14201
- Registration Number
- NCT02769078
Real-World Comparative Observational Study in Non-Valvular Atrial Fibrillation Patients Using Oral Anticoagulants
- Conditions
- Interventions
- First Posted Date
- 2016-04-28
- Last Posted Date
- 2022-05-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 321182
- Registration Number
- NCT02754154
Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer
- First Posted Date
- 2016-04-20
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Alliance Foundation Trials, LLC.
- Target Recruit Count
- 811
- Registration Number
- NCT02744092
- Locations
- 🇺🇸
Washington Hospital, Fremont, California, United States
🇺🇸Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, Florida, United States
🇺🇸Saint Joseph's Medical Center, Stockton, California, United States
Dabigatran Study in the Early Phase of Stroke. New Neuroimaging Markers and Biomarkers Study (SEDMAN STUDY)
- Conditions
- Interventions
- First Posted Date
- 2016-04-19
- Last Posted Date
- 2018-03-20
- Lead Sponsor
- Hospital Mutua de Terrassa
- Target Recruit Count
- 500
- Registration Number
- NCT02742480
- Locations
- 🇪🇸
Hospital Universitari Mutua Terrassa, Terrassa, Barcelona, Spain
APIXABAN in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France SNIIRAM Study
- Conditions
- Interventions
- First Posted Date
- 2015-12-28
- Last Posted Date
- 2022-05-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 321501
- Registration Number
- NCT02640222
Length of Stay in NVAF Patients Hospitalized and Initiated With Dabigatran or Warfarin in Japan
- First Posted Date
- 2015-12-15
- Last Posted Date
- 2018-03-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 4313
- Registration Number
- NCT02631057
- Locations
- 🇯🇵
NISED Center, Tokyo, Shinagawa, Japan
🇯🇵1160.254.81001 Boehringer Ingelheim Investigational Site, Shinagawa, Japan
Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for Acute Intermediate-Risk Pulmonary Embolism.
- First Posted Date
- 2015-11-04
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Prof. Stavros Konstantinides, MD
- Target Recruit Count
- 400
- Registration Number
- NCT02596555
- Locations
- 🇩🇪
Center for Thrombosis and Hemostasis, University Medical Center Mainz, Mainz, Germany
Pleotropic Effect of New Oral Anticoagulants
- First Posted Date
- 2015-09-09
- Last Posted Date
- 2015-09-09
- Lead Sponsor
- Kyunghee University Medical Center
- Target Recruit Count
- 55
- Registration Number
- NCT02544932
- Locations
- 🇰🇷
Kyung Hee University, Seoul, Korea, Republic of
Effect of Inhibitors of the Proton Pump on Intestinal Transporters
- Conditions
- Interventions
- First Posted Date
- 2015-08-14
- Last Posted Date
- 2016-01-25
- Target Recruit Count
- 12
- Registration Number
- NCT02524210
- Locations
- 🇫🇷
CHU de SAINT-ETIENNE, Saint-etienne, France
Canadian Pradaxa Acute Stroke Safety Study
- Conditions
- First Posted Date
- 2015-04-14
- Last Posted Date
- 2020-06-19
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 101
- Registration Number
- NCT02415855
- Locations
- 🇨🇦
University of Alberta, Edmonton, Alberta, Canada
🇨🇦Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.